These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3057852)

  • 1. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration.
    Pollick C
    Am J Cardiol; 1988 Dec; 62(17):1252-5. PubMed ID: 3057852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy.
    Hartmann A; Kühn J; Hopf R; Klepzig H; Standke R; Kober G; Maul FD; Hör G; Kaltenbach M
    Cardiology; 1992; 80(2):81-8. PubMed ID: 1611637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
    Pollick C; Kimball B; Henderson M; Wigle ED
    Am J Cardiol; 1988 Dec; 62(17):1248-51. PubMed ID: 3195486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of disopyramide and propranolol in hypertrophic cardiomyopathy.
    Cokkinos DV; Salpeas D; Ioannou NE; Christoulas S
    Can J Cardiol; 1989; 5(1):33-6. PubMed ID: 2920304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol--a case report.
    Tokudome T; Mizushige K; Ueda T; Sakamoto S; Matsuo H
    Angiology; 1999 Apr; 50(4):331-5. PubMed ID: 10225470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.
    Matsubara H; Nakatani S; Nagata S; Ishikura F; Katagiri Y; Ohe T; Miyatake K
    J Am Coll Cardiol; 1995 Sep; 26(3):768-75. PubMed ID: 7642872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy.
    Sherrid M; Delia E; Dwyer E
    Am J Cardiol; 1988 Nov; 62(16):1085-8. PubMed ID: 3189171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy.
    Kimball BP; Bui S; Wigle ED
    Am Heart J; 1993 Jun; 125(6):1691-7. PubMed ID: 8498312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children.
    Duncan WJ; Tyrrell MJ; Bharadwaj BB
    Can J Cardiol; 1991 Mar; 7(2):81-6. PubMed ID: 2049687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
    Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
    G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Doppler and echocardiographic assessments of effects of disopyramide on non-obstructive hypertrophic cardiomyopathy].
    Nagashima J
    J Cardiol; 1991; 21(1):75-86. PubMed ID: 1817183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of concurrent oral administration of propranolol and disopyramide on cardiac function in healthy men.
    Cathcart-Rake WF; Coker JE; Atkins FL; Huffman DH; Hassanein KM; Shen DD; Azarnoff DL
    Circulation; 1980 May; 61(5):938-45. PubMed ID: 7363436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy.
    Sumimoto T; Hamada M; Ohtani T; Shigematsu Y; Fujiwara Y; Sekiya M; Hiwada K
    J Clin Pharmacol; 1991 May; 31(5):440-3. PubMed ID: 2050829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Left ventricular function at rest and during exercise and the effects of propranolol in patients with hypertrophic cardiomyopathy].
    Amano K; Sakamoto T; Sugimoto T
    J Cardiol Suppl; 1987; 16():35-51. PubMed ID: 3509682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy.
    Hongo M; Nakatsuka T; Takenaka H; Tanaka M; Watanabe N; Yazaki Y; Sekiguchi M
    Cardiology; 1996; 87(1):6-11. PubMed ID: 8631046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative study of the effects of verapamil and propranolol therapy in 16 cases of obstructive hypertrophic myocardiopathy].
    Cosnay P; Fauchier JP; Lang M; Casset D; Raynaud P; Lavigne G; Itti R
    Arch Mal Coeur Vaiss; 1987 Mar; 80(3):346-55. PubMed ID: 3113357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic efficacy of Ethmozine (moricizine HCl) compared with disopyramide and propranolol.
    Pratt CM; Butman SM; Young JB; Knoll M; English LD
    Am J Cardiol; 1987 Oct; 60(11):52F-58F. PubMed ID: 3310586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide.
    Pollick C
    N Engl J Med; 1982 Oct; 307(16):997-9. PubMed ID: 7202121
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.